Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin and Occupational Therapy for Writer's Cramp
NCT02015039Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of neuronox in writer's cramp (FHD) (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Visual Analogue Scale at 20 weeks. Started Dec 2013; status: completed.
02
Drugs
neuronox
03
Conditions
writer's cramp (FHD)
Beyond the preview
Go deeper on NCT02015039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015039.